logo-loader
viewAmphion Innovations PLC

Loan facility update

/**/ h1{margin-top:24.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;line-height:115%;font-size:24.0pt;font-family:"Calibri","sans-serif";color:black;font-weight:bold;}h2{margin-top:18.0pt;margin-right:0cm;margin-bottom:4.0pt;margin-left:0cm;line-height:115%;font-size:18.0pt;font-family:"Calibri","sans-serif";color:black;font-weight:bold;}h3{margin-top:14.0pt;margin-right:0cm;margin-bottom:4.0pt;margin-left:0cm;line-height:115%;font-size:14.0pt;font-family:"Calibri","sans-serif";color:black;font-weight:bold;}h4{margin-top:12.0pt;margin-right:0cm;margin-bottom:2.0pt;margin-left:0cm;line-height:115%;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;font-weight:bold;}h5{margin-top:11.0pt;margin-right:0cm;margin-bottom:2.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;font-weight:bold;}h6{margin-top:10.0pt;margin-right:0cm;margin-bottom:2.0pt;margin-left:0cm;line-height:115%;font-size:10.0pt;font-family:"Calibri","sans-serif";color:black;font-weight:bold;}p{margin-top:5.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:0cm;line-height:115%;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;}body{ }link{ color: #000000 }visited{ color: fuchsia } .ai{size:595.0pt 842.0pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.ai{}p.bq{margin:0cm;margin-bottom:.0001pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border: none; font-weight: bold; line-height: normal; text-align: center}span.bo{font-variant:small-caps}p.br{margin:0cm;margin-bottom:.0001pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border: none; font-weight: bold; line-height: normal}p.bs{margin-right:0cm;margin-left:0cm;line-height:normal;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: center}p.bt{margin-right:0cm;margin-left:0cm;line-height:normal;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;margin:0cm;margin-bottom:.0001pt;text-align:justify}p.bu{margin-right:0cm;margin-left:0cm;line-height:normal;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;margin:0cm;margin-bottom:.0001pt;text-align:justify}p.bv{margin-right:0cm;margin-left:0cm;line-height:normal;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;font-div: italic; margin: 0cm; margin-bottom: .0001pt}p.bw{margin:0cm;margin-bottom:.0001pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;font-weight: bold; line-height: normal} table.bx{margin-left:5.65pt;border-collapse:collapse}tr.be{height:12.0pt}td.bh{width:216.05pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:12.0pt}td.bf{width:219.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:12.0pt}p.by{margin:0cm;margin-bottom:.0001pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border: none; line-height: normal; text-align: right}p.bz{margin:0cm;margin-bottom:.0001pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;line-height:normal;border:none}p.ca{margin:0cm;margin-bottom:.0001pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;line-height:normal}tr.az{height:24.0pt}td.bb{width:317.9pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:24.0pt}td.ba{width:117.15pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:24.0pt} td.ay{width:259.25pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:12.0pt}td.ax{width:175.8pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:12.0pt}td.aw{width:216.05pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:24.0pt}td.av{width:219.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:24.0pt}span.au{color:#1A1A1A}td.at{width:251.25pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:12.0pt}td.as{width:183.8pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:12.0pt}td.ar{width:147.7pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:12.0pt}td.ap{width:287.35pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:12.0pt}span.aq{color: blue; text-decoration: underline} td.ao{border:none}p.cb{margin:0cm;margin-bottom:.0001pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border: none; font-weight: bold; line-height: normal; text-align: justify}p.cc{margin:0cm;margin-bottom:.0001pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;text-align:justify;line-height:normal;border:none}span.ak{text-decoration: underline}p.cd{margin:0cm;margin-bottom:.0001pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;margin-top:5.0pt;margin-right:0cm;margin-bottom:5.0pt; margin-left:0cm;text-align:justify;line-height:normal} /**/
RNS Number : 8862B
Amphion Innovations PLC
12 June 2019
 

AMPHION INNOVATIONS PLC

 ("Amphion" or "the Company")

  

Loan facility update

 

12 June 2019, London and New York - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces an update in respect of its loan facility.

 

The Company has been notified by the Company's debt provider (the "Lender") that, further to the terms of the loan facility which were announced on 11 March 2019 and 1 April 2019 (the "Facility"), the excess value of the collateral above the loan balance does not presently meet the terms of the Facility. As of 11 June 2019, the loan balance outstanding pursuant to the Facility is approximately US $3.2 million (including fees and accrued interest) and the number of Motif shares held was 10,900,591.  The Board is working closely with the Lender regarding potential resolution in connection with the collateral requirement and further announcements will be made as appropriate. 

 

The Company remains highly cash constrained and continues to consider both its short term and medium term funding options and work with the Company's note holders. The outstanding Facility balance plus accrued interest are currently due for repayment on 30 September 2019. 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 

For further information please contact:

 

Amphion Innovations

Tel: +1 (212) 210 6224

Charlie Morgan




Panmure Gordon Limited (Nominated Adviser and Corporate Broker)

Tel: +44 (0)20 7886 2500

Emma Earl/ Freddy Crossley  (Corporate Finance)


Charles Leigh-Pemberton (Corporate Broking)




SP Angel Corporate Finance LLP (Joint Corporate Broker)

Tel: +44 (0) 20 3470 0470

David Hignell (Corporate Finance)


Vadim Alexandre (Corporate Broking)




Walbrook PR

Tel: +44 (0)20 7933 8780 or [email protected]

Anna Dunphy / Paul McManus


 

 

 

About Amphion Innovations plc

Amphion Innovations is a developer of medical, life science and technology businesses. We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.

 

On the web: www.amphionplc.com

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCEANKFFALNEFF

Quick facts: Amphion Innovations PLC

Price: 0.15

Market: AIM
Market Cap: £314.96 k
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Amphion Innovations president on significant partner developments and strategy

Bob Bertoldi, president of Amphion Innovations PLC (LON:AMP) caught up with Proactive London’s Andrew Scott to discuss some of the big 2018 developments at the partner companies including Polarean Imaging (LON:POLX) and Motif Bio PLC (LON:MTFB) Polarean’s recently raised US$4mln through a...

on 14/12/18